Skip to main content


Monday, February 26, 2024
Gene/Cell Therapy
Sernova is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and hemophilia A. The Company is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes with the Cell Pouch System™, a novel implantable and scalable cell therapy platform transplanted initially with human donor islets but ultimately using an iPSC islet like cluster technology exclusively licensed from Evotec SE. The company is currently progressing a Phase 1/2 clinical trial evaluating the Cell Pouch System in patients with T1D with impaired hypoglycemia awareness. Of six patients in the first cohort of the trial, five are now insulin-independent, with the first patient at almost four years without the need for insulin injections and a normalized HbA1c. Enrollment in a second cohort of 7 patients is complete, with data to come in early 2024.
Cynthia Pussinen, CEO - Sernova Corp.



Website please note that the site is under reconstruction

CEO/Top Company Official

Cynthia Pussinen, CEO

Lead Product in Development

Human donor islets delivered via the cell pouch; for insulin dependent type 1 diabetes; next study will be using iPSCs

Development Phase of Primary Product

Phase II

Number Of Unlicensed Products


Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.